Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Decitabine,Decitabine2023-US-01,2023,USA,MDV,350,68,45,55,27.5,62,78,5,15,30,40,15,55,25,15,5,20,35,45,18,8,4,10,6,22,38,45,FLT3 inhibitors,7+3 Cytarabine and Daunorubicin,5-Azacitidine,LDAC,0,0,0,25,60,40,15,55,30,65,
Decitabine,Decitabine2022-EU-02,2022,Germany,Claim Database,420,72,48,52,26.8,58,75,7,12,28,42,18,52,28,14,6,18,33,49,20,10,5,12,7,20,35,42,FLT3 inhibitors,7+3 Cytarabine and Daunorubicin,5-Azacitidine,LDAC,0,0,0,28,62,42,12,52,36,68,
Decitabine,Decitabine2024-Asia-03,2024,Japan,MDV,280,65,42,58,25.5,55,80,3,18,32,38,12,58,22,16,4,22,37,41,16,7,3,9,5,24,40,47,FLT3 inhibitors,7+3 Cytarabine and Daunorubicin,5-Azacitidine,LDAC,0,0,0,23,58,38,18,58,24,62,
